PMID- 37750649
OWN - NLM
STAT- MEDLINE
DCOM- 20230927
LR  - 20231019
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 27
IP  - 17
DP  - 2023 Sep
TI  - Effect of Ezetimibe combined with Simvastatin in the treatment of coronary heart 
      disease: a retrospective analysis.
PG  - 8212-8217
LID - 33581 [pii]
LID - 10.26355/eurrev_202309_33581 [doi]
AB  - OBJECTIVE: The aim of this study was to explore the effect of Ezetimibe combined 
      with Simvastatin in the treatment of coronary heart disease (CHD). PATIENTS AND 
      METHODS: Clinical data of 101 patients with CHD, admitted to our hospital from 
      February 2022 to May 2023, were retrospectively analyzed. Among them, 49 patients 
      received Simvastatin (Simvastatin group), and 52 patients received 
      Simvastatin+Ezetimibe (Simvastatin+Ezetimibe group). Levels of blood lipid 
      indicators, inflammatory factors, cardiac function indicators, and incidences of 
      major adverse cardiovascular events (MACE) between the two groups were compared 
      before and after the treatment. RESULTS: After the treatment, high-density 
      lipoprotein cholesterol (HDL-C), cardiac index (CI), and left ventricular 
      ejection fraction (LVEF) in both groups were higher than those before the 
      treatment, and overall higher in the Simvastatin+Ezetimibe group. Levels of 
      low-density lipoprotein-cholesterol (LDL-C), triglycerides (TG), total 
      cholesterol (TC), monocyte chemoattractant protein-1 (MCP-1), chemokine ligand 19 
      (CCL19), high sensitivity C-reactive protein (hs-CRP), cardiac output (CO) in the 
      two groups were lower than before the treatment. These indexes were significantly 
      lower in the Simvastatin+Ezetimibe group (p<0.05) compared to the Simvastatin 
      group. During the treatment, the incidence of MACE in the Simvastatin+Ezetimibe 
      group (3.85%) was significantly lower than that in the Simvastatin group (16.33%) 
      (p<0.05). CONCLUSIONS: Compared with Simvastatin alone, a combination of 
      Ezetimibe and Simvastatin can more effectively regulate the level of blood 
      lipids, reduce the inflammatory reaction in the body, improve heart function, and 
      lower the risk of MACE.
FAU - Li, B
AU  - Li B
AD  - Department of Biochemistry and Molecular Biology, The Key Laboratory of Neural 
      and Vascular Biology, China Administration of Education, Hebei Medical 
      University, Shijiazhuang, Hebei Province, China. xuzeshengcz@163.com.
FAU - Li, Y
AU  - Li Y
FAU - Peng, W-Z
AU  - Peng WZ
FAU - Liu, Y-Q
AU  - Liu YQ
FAU - Xu, Z-S
AU  - Xu ZS
FAU - Wen, J-K
AU  - Wen JK
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 9007-41-4 (C-Reactive Protein)
RN  - 0 (Cholesterol, HDL)
RN  - EOR26LQQ24 (Ezetimibe)
SB  - IM
MH  - Humans
MH  - Retrospective Studies
MH  - Stroke Volume
MH  - *Ventricular Function, Left
MH  - *Coronary Disease/drug therapy
MH  - C-Reactive Protein
MH  - Cholesterol, HDL
MH  - Ezetimibe/therapeutic use
EDAT- 2023/09/26 13:43
MHDA- 2023/09/27 06:42
CRDT- 2023/09/26 08:33
PHST- 2023/09/27 06:42 [medline]
PHST- 2023/09/26 13:43 [pubmed]
PHST- 2023/09/26 08:33 [entrez]
AID - 33581 [pii]
AID - 10.26355/eurrev_202309_33581 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2023 Sep;27(17):8212-8217. doi: 
      10.26355/eurrev_202309_33581.